91 related articles for article (PubMed ID: 9708511)
21. Assessment of cancer recurrence in residual tumors after fractionated radiotherapy: a comparison of fluorodeoxyglucose, L-methionine and thymidine.
Reinhardt MJ; Kubota K; Yamada S; Iwata R; Yaegashi H
J Nucl Med; 1997 Feb; 38(2):280-7. PubMed ID: 9025756
[TBL] [Abstract][Full Text] [Related]
22. Serial FDG-PET studies in the prediction of survival in patients with primary brain tumors.
Schifter T; Hoffman JM; Hanson MW; Boyko OB; Beam C; Paine S; Schold SC; Burger PC; Coleman RE
J Comput Assist Tomogr; 1993; 17(4):509-61. PubMed ID: 8392523
[TBL] [Abstract][Full Text] [Related]
23. PET scanning and the human immunodeficiency virus-positive patient.
O'Doherty MJ; Barrington SF; Campbell M; Lowe J; Bradbeer CS
J Nucl Med; 1997 Oct; 38(10):1575-83. PubMed ID: 9379195
[TBL] [Abstract][Full Text] [Related]
24. [Synthesis and preliminary studies of O-(2-[18F] fluoroethyl)-L-tyrosine as a positron emission tomography imaging agent].
Dang YH; Wang SZ; Cheng X; Zhou Q
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2002 Aug; 24(4):370-2. PubMed ID: 12905655
[TBL] [Abstract][Full Text] [Related]
25. Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography.
Glantz MJ; Hoffman JM; Coleman RE; Friedman AH; Hanson MW; Burger PC; Herndon JE; Meisler WJ; Schold SC
Ann Neurol; 1991 Apr; 29(4):347-55. PubMed ID: 1929205
[TBL] [Abstract][Full Text] [Related]
26. Evidence of 18F-FCH Uptake in Human T98G Glioblastoma Cells.
Buroni FE; Pasi F; Persico MG; Lodola L; Aprile C; Nano R
Anticancer Res; 2015 Dec; 35(12):6439-43. PubMed ID: 26637854
[TBL] [Abstract][Full Text] [Related]
27. Fluorine-18-fluorodeoxyglucose PET versus thallium-201 scintigraphy evaluation of thyroid tumors.
Uematsu H; Sadato N; Ohtsubo T; Tsuchida T; Nakamura S; Sugimoto K; Waki A; Takahashi N; Yonekura Y; Tsuda G; Saito H; Hayashi N; Yamamoto K; Ishii Y
J Nucl Med; 1998 Mar; 39(3):453-9. PubMed ID: 9529291
[TBL] [Abstract][Full Text] [Related]
28. Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy.
Akabani G; Cokgor I; Coleman RE; González Trotter D; Wong TZ; Friedman HS; Friedman AH; Garcia-Turner A; Herndon JE; DeLong D; McLendon RE; Zhao XG; Pegram CN; Provenzale JM; Bigner DD; Zalutsky MR
Int J Radiat Oncol Biol Phys; 2000 Mar; 46(4):947-58. PubMed ID: 10705017
[TBL] [Abstract][Full Text] [Related]
29. Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine.
Wang W; Larson SM; Tuttle RM; Kalaigian H; Kolbert K; Sonenberg M; Robbins RJ
Thyroid; 2001 Dec; 11(12):1169-75. PubMed ID: 12186505
[TBL] [Abstract][Full Text] [Related]
30. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M
Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
[TBL] [Abstract][Full Text] [Related]
31. Technetium-99m-labeled HL91 to identify tumor hypoxia: correlation with fluorine-18-FDG.
Cook GJ; Houston S; Barrington SF; Fogelman I
J Nucl Med; 1998 Jan; 39(1):99-103. PubMed ID: 9443745
[TBL] [Abstract][Full Text] [Related]
32. Prediction of survival in glioma patients by means of positron emission tomography.
Patronas NJ; Di Chiro G; Kufta C; Bairamian D; Kornblith PL; Simon R; Larson SM
J Neurosurg; 1985 Jun; 62(6):816-22. PubMed ID: 2987440
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of fluorine-18-BPA-fructose for boron neutron capture treatment planning.
Kabalka GW; Smith GT; Dyke JP; Reid WS; Longford CP; Roberts TG; Reddy NK; Buonocore E; Hübner KF
J Nucl Med; 1997 Nov; 38(11):1762-7. PubMed ID: 9374349
[TBL] [Abstract][Full Text] [Related]
34. Quantitative studies of monoclonal antibody targeting to disialoganglioside GD2 in human brain tumors.
Arbit E; Cheung NK; Yeh SD; Daghighian F; Zhang JJ; Cordon-Cardo C; Pentlow K; Canete A; Finn R; Larson SM
Eur J Nucl Med; 1995 May; 22(5):419-26. PubMed ID: 7641750
[TBL] [Abstract][Full Text] [Related]
35. FDG hypermetabolism associated with inflammatory necrotic changes following radiation of meningioma.
Fischman AJ; Thornton AF; Frosch MP; Swearinger B; Gonzalez RG; Alpert NM
J Nucl Med; 1997 Jul; 38(7):1027-9. PubMed ID: 9225785
[TBL] [Abstract][Full Text] [Related]
36. PET imaging drug distribution after intratumoral injection: the case for (124)I-iododeoxyuridine in malignant gliomas.
Roelcke U; Hausmann O; Merlo A; Missimer J; Maguire RP; Freitag P; Radü EW; Weinreich R; Gratzl O; Leenders KL
J Nucl Med; 2002 Nov; 43(11):1444-51. PubMed ID: 12411546
[TBL] [Abstract][Full Text] [Related]
37. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma.
Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
Haematologica; 2000 Jun; 85(6):613-8. PubMed ID: 10870118
[TBL] [Abstract][Full Text] [Related]
38. 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma.
Barker FG; Chang SM; Valk PE; Pounds TR; Prados MD
Cancer; 1997 Jan; 79(1):115-26. PubMed ID: 8988735
[TBL] [Abstract][Full Text] [Related]
39. Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results.
Brown MT; Coleman RE; Friedman AH; Friedman HS; McLendon RE; Reiman R; Felsberg GJ; Tien RD; Bigner SH; Zalutsky MR; Zhao XG; Wikstrand CJ; Pegram CN; Herndon JE; Vick NA; Paleologos N; Fredericks RK; Schold SC; Bigner DD
Clin Cancer Res; 1996 Jun; 2(6):963-72. PubMed ID: 9816257
[TBL] [Abstract][Full Text] [Related]
40. FDG-PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma.
van Ginkel RJ; Hoekstra HJ; Pruim J; Nieweg OE; Molenaar WM; Paans AM; Willemsen AT; Vaalburg W; Koops HS
J Nucl Med; 1996 Jun; 37(6):984-90. PubMed ID: 8683328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
